



Financial Tear Sheet

Corporate Profile

Quest Diagnostics is the world's leading provider of diagnostic information services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Primary IR Contact

Shawn Bevec
Executive Director Investor Relations
Phone: 973-520-2900
Investor@QuestDiagnostics.com

Stock Performance

DGX (Common Stock)	
Exchange	NYSE (US Dollar)
Price	\$107.98
Change (%)	▼ 0.16 (0.15%)
Volume	573,268
52 Week Low	\$75.20
Market Cap	\$14,774,419,758
Rolling EPS	4.96
PE Ratio	21.77
Shares Outstanding	136,825,521
Data as of 05/26/17 4:02 p.m. ET	

■ QUEST DIAGNOSTICS INC
as of 5/26/2017



EDGAR Online

Recent Press Releases

05/16/17
Increases in Illicit Drugs, Including Cocaine, Drive Workforce Drug Positivity to Highest Rate in 12 Years, Quest Diagnostics Analysis Finds

05/16/17
Quest Diagnostics Declares Quarterly Cash Dividend

05/12/17
Quest Diagnostics To Speak At The UBS Global Healthcare Conference

Upcoming Events


Date	Title
07/25/17	Q2 2017 Quest Diagnostics Earnings Conference Call

Recent SEC Filings

Filing Date	Form	Description
05/23/17	4	Statement of changes in beneficial ownership of securities
05/19/17	8-K	Report of unscheduled material events or corporate event
05/18/17	4	Statement of changes in beneficial ownership of securities
05/18/17	4	Statement of changes in beneficial ownership of securities

Analyst Estimates / Ratings

Mean Recommendation: 2.7



Board of Directors

Stephen H. Rusckowski

Chairman, President and Chief Executive Officer

Dan C. Stanzione, Ph.D.

Lead Independent Director

Jenne K. Britell, Ph.D.

Director

Vicky B. Gregg

Director

Jeffrey M. Leiden, M.D., Ph.D.

Director

Timothy L. Main

Director

Gary M. Pfeiffer

Director

Timothy M. Ring

Director

Gail R. Wilensky, Ph.D.

Director

EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Jun 17	1.42	1.42	1.43
QTR	Sep 17	1.43	1.43	1.45
QTR	Dec 17	1.39	1.39	1.39
QTR	Mar 18	1.33	1.33	1.27
FY	Dec 17	5.56	5.56	5.46
FY	Dec 18	5.87	5.86	5.79

Management Team

Stephen H. Rusckowski

Chairman, President and Chief Executive Officer

Jon R. Cohen, M.D.

Senior Vice President and Group Executive – Diagnostic Solutions

Everett Cunningham

Senior Vice President, Commercial

James E. Davis

Executive Vice President, General Diagnostics

Catherine T. Doherty

Senior Vice President and Group Executive – Clinical Franchise Solutions & Marketing

Carrie Eglinton Manner

Senior Vice President, Advanced Diagnostics

Lidia Fonseca

Senior Vice President and Chief Information Officer

Mark J. Guinan

Executive Vice President and Chief Financial Officer

John B. Haydon

Vice President, Global Markets and Chairman, Q² Solutions

Michael E. Prevoznik

Senior Vice President and General Counsel

Jeffrey S. Shuman

Senior Vice President, Chief Human Resources Officer

Gary D. Samuels

Vice President, Corporate Communications

Tim Sharpe

Vice President, Compliance

Dermot Shorten

Senior Vice President, Strategy, M&A and Ventures

Jay G. Wohlgemuth M.D.

Senior Vice President, R&D, Medical and Chief Medical Officer

Ownership Summary

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
The Vanguard Group, Inc.	13,504,122	9.9	-50,485	03/31/17
Delaware Investments	8,328,711	6.1	-211,725	03/31/17
BlackRock Institutional Trust Company, N.A.	7,740,423	5.7	121,540	03/31/17
State Street Global Advisors (US)	6,918,900	5.1	180,690	03/31/17
BlackRock Financial Management, Inc.	3,847,562	2.8	-927,928	03/31/17
LSV Asset Management	3,150,309	2.3	-216,050	03/31/17
Bessemer Trust Company, N.A. (US)	2,459,254	1.8	52,036	03/31/17
American Century Investment Management, Inc.	2,132,929	1.6	-126,847	03/31/17
Capital Research Global Investors	2,090,000	1.5	0	03/31/17
Capital International Investors	2,090,000	1.5	0	03/31/17